NTRK1 and neoplasm: TRK-inhibitors were the first drugs to get tumor-agnostic approval by The European Medicines Agency (EMA) [8], meaning that the drug is approved for all tumors with NTRK-fusion, irrespective of the origin of the tumor or histopathological type.